TNF and colonic neoplasm: The topoisomerase inhibitor SN38, an active metabolite of irinotecan, causes cytotoxicity through the TNF/TNFR signaling pathway in a panel of colon cancer cells and promotes the progression of necroptosis, [123], suggesting its potential use in the treatment of CRC [157].